NCT02613871View on ClinicalTrials.gov

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

PHASE3CompletedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

January 4, 2017

Study Completion Date

November 7, 2018

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

Trial Locations (8)

Unknown

Changhua

Chiayi City

Kaohsiung City

Keelung

Taichung

Tainan City

Taipei

Taoyuan District

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT02613871 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection | Biotech Hunter | Biotech Hunter